Novelty, Conformity and Trust in COVID-19 Vaccines

NACompletedINTERVENTIONAL
Enrollment

35,180

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

March 30, 2021

Study Completion Date

March 30, 2021

Conditions
Trust
Interventions
OTHER

RNA vaccine

We elicit subjects' willingness to receive RNA COVID-19 vaccine

OTHER

20% adoption rate

We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it

OTHER

40% adoption rate

We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it

OTHER

60% adoption rate

We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it

OTHER

80% adoption rate

We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it

OTHER

Conventional vaccine

We elicit subjects' willingness to receive conventional COVID-19 vaccine

OTHER

0% adoption rate

We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it

Trial Locations (1)

94403

SurveyMonkey, San Mateo

All Listed Sponsors
lead

National University of Singapore

OTHER

NCT04693689 - Novelty, Conformity and Trust in COVID-19 Vaccines | Biotech Hunter | Biotech Hunter